Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer
10.3760/cma.j.cn371439-20240716-00099
- VernacularTitle:胃癌及食管胃结合部癌免疫及靶向治疗研究进展
- Author:
Yang WU
1
;
Tian LI
;
Runbing ZHANG
;
Tingting SHI
;
Chun GAO
;
Xiaofeng ZHENG
;
Jiucong ZHANG
Author Information
1. 中国人民解放军联勤保障部队第九四〇医院消化内科，兰州 730050
- Keywords:
Stomach neoplasms;
Esophagogastric junction;
Immunotherapy;
Molecular targeted therapy
- From:
Journal of International Oncology
2024;51(9):595-600
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer and esophagogastric junction cancer (EGJC) are one of the world 's most common types of malignant tumors. Traditional treatment methods mainly include radiotherapy, chemotherapy, and surgery, but the patients ' prognosis is limited. In recent years, with the development in treatment methods, immunotherapy and targeted therapy are gradually recognized as the first-line treatment methods. In immunotherapy, nivolumab and pabolizumab have shown clear efficacy in patients with programmed deathligand 1 positive, while other immunotherapies (such as tumor vaccine, engineered T cells, and non-specific immunomodulators) are still being tested or developed. In addition, targeted therapy has only shown comparatively large therapeutic potential in certain specific populations or in second-line treatment. For instance, tratuzumab has a clear curative effect on patients with positive human epidermal growth factor receptor 2, but has suboptimal efficacy in patients with amplification of other molecular targets. An in-depth discussion of the research progress of immunotherapy and targeted therapy in gastric cancer and EGJC will help to improve the prognosis of patients and provide a reference for accurate treatment of tumors.
